A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage.
Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…
Among patients who visited an ophthalmologist over an 8-year period, those with a current prescription for a fluoroquinolone were 4.5 times more likely to have a retinal detachment…The mechanism underlying the association is unknown but is presumed to be related to the destructive effects of fluoroquinolones on collagen and connective tissue. http://www.medpagetoday.com/Ophthalmology/GeneralOphthalmology/32011
Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…
Researchers at Johns Hopkins University (JHU) have created biodegradable, ultra tiny, nanosized particles that can easily slip through the body’s sticky and viscous mucus secretions to deliver a sustained-release medication cargo. The interdisciplinary team of researchers, led by Justin Hanes of the JHU Center for Nanomedicine, developed the nanoparticles so that they not only penetrate…
With more drugmakers outsourcing more trials to contract research organizations, few should be surprised that the CRO sector is generating investor interest. The attention-grabbing deal announced this week in which two private equity firms – Carlyle Group and Hellman & Friedman – agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development is…
“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that treat-and-extend regimens for ranibizumab were efficacious for DME. Further support was provided by the TREX-DME study, the first prospective, randomized controlled…